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A B S T R A C T
Despite the use of pneumococcal conjugate vaccines, the number of infections related to Streptococcus
pneumoniae continues to be alarming.
Herein, we identified, characterized the MSlys endolysin encoded in the phage MS1. We further tested
its antimicrobial efficacy against planktonic and biofilm cells, assessing the culturability of cells and
biofilm structure by scanning electron microscopy, and confocal laser scanning microscopy.
The modular MSlys endolysin consists of an amidase catalytic domain and a choline-binding domain.
MSlys is active against isolates of children with otitis media, and conditions close to those found in the
middle ear. Treatment with MSlys (2 h, 4 mM) reduced planktonic cultures by 3.5 log10 CFU/mL, and 24-
and 48-h-old biofilms by 1.5 and 1.8 log10 CFU/mL, respectively. Imaging of the biofilms showed thinner
and damaged structures compared to control samples.
The recombinantly expressed MSlys may be a suitable candidate for treating pneumococcal infections,
including otitis media.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
S. pneumoniae is a common colonizer of the nasopharynx of
healthy humans since early infancy [1]. It is also responsible for
several infectious diseases such as otitis media and sinusitis, as
well as life-threatening invasive diseases, including pneumonia,
sepsis, and meningitis [1,2]. Despite the implementation of
pneumococcal conjugate vaccines into national immunization
programs, S. pneumoniae continues to be a common cause of
morbidity and mortality worldwide [2], resulting in 1.6 million
deaths every year [3].
Biofilms are communities of microorganisms embedded in a
self-produced extracellular polymeric matrix and attached to a
surface [4], being a common cause of persistent bacterial infections
[5]. Growth in biofilms benefits bacteria protecting against
environmental stresses, host immune defenses, as well as
antimicrobial agents [4]. S. pneumoniae tolerates high antibiotic
concentrations and belongs to the World Health Organization
priority list of pathogens in need for R&D of new antimicrobials [6].
S. pneumoniae phages, such as Dp-1 and Cp-1, have been
isolated and thoroughly characterized. However, they do not infect
encapsulated pneumococcal strains, which are highly prevalent in
disease, limiting phage therapeutic use [7]. More recently, phage
MS1, which is related to the Dp-1 phage (average nucleotide
identity of 73.3 % on 62.3 % of aligned nucleotides), was isolated [8].
Unlike phages, phage endolysins can effectively kill this pathogen.
Shortly after the isolation of Dp-1 and Cp-1 phages, the lytic
enzymes Pal and Cpl-1 were identified. Their ability to kill S.
pneumoniae when applied exogenously was, later on, demonstrat-
ed when used alone [9], together [10], and even combined with
antibiotics [11]. Their antibacterial potential in animal models
mimicking nasopharyngeal colonization [9], bacteremia [12],
endocarditis [13], otitis media [14], among others, provided
excellent results.
Endolysins identified in pneumococcal phages and also
many proteins found in the pneumococcal cell wall (e.g., LytA
autolysin) are characterized by a modular organization. The N-
terminal of these is responsible for the catalytic activity and the C-
terminal for the cell binding. This cell-binding domain is highly
conserved (with the only natural exception being Cpl-7 from the
Cp-7 phage), consisting of several choline-binding repeats that
belong to the CW_binding_1 family and conferring specificity to
these enzymes, which require the presence of choline in the cell
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M.D. Silva, H. Oliveira, A. Faustino et al. Biotechnology Reports 28 (2020) e00547The work described herein focuses on the in silico identification,
ecombinant expression, and characterization of MSlys, a novel
atural endolysin encoded in the pneumococcal phage MS1.
urthermore, its antibacterial activity against S. pneumoniae
lanktonic and biofilm cells, as well as its stability under different
H and temperature, was evaluated.
. Materials and methods
.1. Bacteria, phages, growth conditions, and plasmids
S. pneumoniae R6st was obtained from the Félix d'Hérelle
eference Center for Bacterial Viruses (Université Laval, Quebec,
Canada) along with phages Dp-1 and MS1. Different S. pneumoniae
isolates and Streptococcus and non-streptococcal species were
tested to determine the lytic spectrum of MSlys (Table 1). S.
pneumoniae were grown at 37 C with 5% CO2 in Todd Hewitt Broth
(THB) supplemented with 2 % (w/v) yeast extract (THBye) or in solid
Tryptic Soy Broth (TSB) (TSB + 1.2 % (w/v) agar with 5% sheep blood)
(TSAsb). H. influenzae was grown in Brain Heart Infusion Broth (BHI)
supplemented with 10 mg/mL NAD (VWR) and 10 mg/mL Hemin
(BHINH, 37 C, 5% CO2). M. catarrhalis was grown in BHI (37 C, 5%
CO2), and S. aureus, P. aeruginosa, and E. faecalis were grown in TSB
at 37 C in aerobic conditions. Escherichia coli TOP10 and BL21(DE3)
(Invitrogen, ThermoFisher Scientific) were grown in Lysogeny
Broth (LB) in liquid or solid form (1.2 % (w/v) of agar) at 37 C. The
able 1
he spectrum of activity of MSlys.




Streptococcus pneumoniae R6st Félix d’Hérelle Reference Center for Bacterial Viruses 37 C, 5% CO2 +














































Blood culture, Hospital de Braga +
Streptococcus mitis I3124473 Pus, Hospital de Braga 37 C, 5% CO2 +
I310333 Ocular, Hospital de Braga +
U374030 Pus, Hospital de Braga +
Streptococcus agalactiae (Group B) I302171 Placenta, Hospital de Braga 37 C, 5% CO2 –
I303139 Perianal abscess, Hospital de Braga –
Streptococcus anginosus (Anginosus
group)
U365575 Pus, Hospital de Braga 37 C, 5% CO2 –
I298561 Blood culture, Hospital de Braga –
Streptococcus bovis (Group D) U344929 Urine, Hospital de Braga 37 C, 5% CO2 –
U238779 Pleural washout, Hospital de Braga –
Streptococcus constellatus
(Anginosus group)
I303868 Periamydral abscess, Hospital de Braga 37 C, 5% CO2 –
Streptococcus pyogenes (Group A) C124992 Ocular, Hospital de Braga 37 C, 5% CO2 –
U164028 Auricular, Hospital de Braga –
Streptococcus salivarius I299612 Blood, Hospital de Braga 37 C, 5% CO2 –
Streptococcus Group C U269790 Hemolysis, Hospital de Braga 37 C, 5% CO2 –
Streptococcus Group G U284971 Hemolysis, Hospital de Braga 37 C, 5% CO2 –
I196480 Oropharynx, Hospital de Braga –
Haemophilus influenzae C894248 Sputum, Hospital de Braga 37 C, 5% CO2 –
Moraxella catarrhalis U225012 Ocular, Hospital de Braga 37 C, 5% CO2 –
Staphylococcus aureus ATCC 6358 Human lesion, American Type Culture Collection 37 C –
Pseudomonas aeruginosa PAO1 (DSM 22644) Infected wound, DSMZ – German Collection of Microorganisms and Cell
Cultures GmbH
37 C –
Enterococcus faecalis I809 Urine, Hospital de Braga 37 C –
he activity of MSlys was considered positive (+) if it resulted in a reduction of the optical density greater than 30 % after 2 h of incubation at 37 C, using PBS as a negative control.
2
M.D. Silva, H. Oliveira, A. Faustino et al. Biotechnology Reports 28 (2020) e00547plasmid pET-28a(+) was purchased from Novagen (EMD Bio-
sciences, Inc., Germany).
2.2. In silico identification and characterization of MSlys
The genome of Streptococcus phage MS1 (Accession No.
KY629621.2) was analyzed to identify putative endolysins, and
similarities to other endolysins searched using BLASTP. The
search for functional domains was completed using both Pfam
[16] and PROSITE [17], the molecular weight and isoelectric point
predicted using ExPASy ProtParam [18], and protein alignment
with other streptococcal endolysins was done with ClustalW 2.1
[19].
2.3. Cloning
DNA was extracted from phage lysates using the phenol:
chloroform extraction method [20]. Open reading frames (ORFs)
encoding MSlys and Pal were amplified by PCR (see primers,
Table 2) using Phusion DNA Polymerase (ThermoScientific, MA,
USA) following the manufacturer’s instructions. PCR products were
purified (D4005, ZYMO RESEARCH, CA, USA), double-digested with
NdeI and HindIII-HF (NEB, MA, USA), and ligated to the pET-28a(+)
vector using T4 DNA ligase. The insertion of the correct sequences
into the plasmids was confirmed by Sanger sequencing. pET-
28a_MSlys and pET-28a_Pal were propagated and maintained in E.
coli TOP10.
2.4. Recombinant protein expression and purification
E. coli BL21(DE3) cells with the recombinant plasmids were
grown in 100 mL LB supplemented with 50 mg/mL of kanamycin
(120 rpm, Orbital Shaker ES-20/60, BIOSAN, Latvia) to an optical
density at 620 nm (OD620) of 0.5. Recombinant protein expression
was induced with 0.5 mM IPTG, and cells incubated overnight
(16 C, 200 rpm, Orbital Shaker MIR-S100, PHCbi, Japan). Cells were
harvested (9000 g, 30 min, 4 C), resuspended in 5 mL of cold lysis
buffer (20 mM NaH2PO4, 0.5 M NaCl, pH 7.4), and disrupted
through 3 cycles of freeze-thawing (80 C to 30 C). This was
followed by 10 cycles of sonication on ice (30-sec pulse, 30-sec
pause, 30 % amplitude, Cole-Parmer Ultrasonic processor, CP-750,
Illinois, USA). Insoluble cell debris was removed by centrifugation
(9000 g, 20 min, 4 C). The supernatant was collected and filtered
through a 0.22 mm PES membrane. Purification was performed
through 0.5 mL Ni2+-NTA agarose (HisPurTM Ni-NTA Resin, Thermo
Scientific) stacked in a gravity flow column using imidazole
concentrations (25300 mM) [21]. Purified proteins were ana-
lyzed by SDS-PAGE, followed by BlueSafe staining (NZYTech,
Lisbon, Portugal). Endotoxins of the first and second elutions were
removed using ToxOut Rapid Endotoxin Removal Kit (BioVision
Inc., Gentaur Molecular Products BVBS, Kampenhout, Belgium).
The buffer was exchanged to PBS (8 g/L NaCl, 0.2 g/L, 1.44 g/L
Na2HPO4, 0.24 g/L KH2PO4, pH 7.4) using Amicon Ultra1 0.5 mL
(Merck). The protein concentration was determined using the
PierceTM BCA Protein Assay Kit (Thermo Scientific).
2.5. Circular dichroism (CD)
Secondary structures of MSlys and Pal were analyzed by circular
dichroism (CD) spectroscopy in the far-UV region (190260 nm),
using a Jasco J-1500 CD spectrometer as performed previously [22].
Secondary structure estimation was made using CDSSTR [23] and
CONTINLL [24] routine of the DICHROWEB [25], and the analysis
complemented using PSIPRED [26].
2.6. Lytic spectra
The spectrum of MSlys was determined using different bacteria
(Table 1). Bacteria were grown overnight, cells harvested [5000 g,
5 min, room temperature (RT)], and resuspended in PBS. MSlys
(20 mL, final concentration of 2 mM) or PBS (20 mL, negative
control) and 180 mL of the bacterial culture were added and
incubated at 37 C with or without 5 % CO2 (depending on the
species tested). The endolysin was considered active if there was at
least a 30 % decrease in OD620 within the 2 h assay.
For serotyping of S. pneumoniae strains, a multiplex PCR using
sets of primers that target different serotypes (1, 2, 3, 4, 5, 6A/B, 6C/
D, 7A/F, 7C, 9 V/9A, 9 N/L, 11A, 12 F/12A/12B/44/46, 14, 15B/C, 16 F,
17 F, 18A/B/C, 19A, 19 F, 20, 22 F/22A, 23 F, 23B, 23A and 33 F/33A/
37) as well as the capsular polysaccharide (cps) locus was
performed (Table S1) [27,28]. Bacterial colonies were resuspended
in 200 mL of NZY bacterial cell lysis buffer (NZYTech, Lisbon,
Portugal), followed by heating at 95 C for 15 min. The Xpert Taq
DNA Polymerase (Grisp, Porto, Portugal) was used for the
multiplex PCR reaction following the manufacturer’s instructions.
2.7. Effect of pH, temperature, and choline on the activity of MSlys
S. pneumoniae R6st cells grown overnight were diluted 1:100 in
fresh THBye and allowed to grow until the exponential phase. The
thermostability of MSlys was assessed by heating the endolysin
samples at several temperatures for 30 min. These samples were
after cooled on ice (20 min), cells harvested (5000 g, 5 min, RT),
and resuspended in PBS. The influence of pH on MSlys activity was
tested on harvested cells resuspended in universal buffer (150 mM
KCl, 10 mM KH2PO4, 10 mM Na3C6H5O7, and 10 mM H3BO3)
adjusted to a range of pH (5–10). For the evaluation of choline
supplementation, harvested cells were resuspended in PBS
containing different choline chloride (VWR) concentrations. The
antibacterial effect of MSlys (2 mM) was determined as described
above (37 C, 5% CO2), with the OD620 of MSlys-treated S.
pneumoniae measured after 30 min, 1 h, and 2 h.
2.8. Antibacterial activity against planktonic cells
Antibacterial assays were performed as previously [22] with
slight modifications. S. pneumoniae R6st cells, grown in THBye
overnight, were 1:100 diluted in fresh media and grown to the
exponential phase. After, they were 100-fold diluted in PBS. Each
culture (50 mL) was incubated at 37 C with 5 % CO2, for 30 min, 1 h
or 2 h with 50 mL of endolysin at 2 mM or 4 mM, or PBS (negative
control). The effect was evaluated by 10-fold diluting in saline (0.9
Table 2
List of primers used to clone the endolysins and their main characteristics. The restriction sites of the enzymes are underlined.Endolysin Primer name Primer sequence Restriction enzyme Tm (C) % GC Product size (bp)
MSlys MS_FW GGTTTCATATGGGAGTAAATATTGATGAAGGCGTTGC NdeI 59.2 41.4 906
MS_RV CCCAAGCTTCTACTTAGTAGTAATGAGCCCGTCAGG HindIII 57.7 48.1
Pal Pal_FW GGTTTCATATGGGAGTCGATATTGAAAAAGGCGTTGC NdeI 61.1 44.8 909
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olony-forming units (CFU).
.9. Colony biofilm formation and endolysin treatment
Overnight grown S. pneumoniae R6st cells were diluted to
pproximately 1 106 CFU/mL, and biofilms formed for 24, and
8 h on polycarbonate membranes (0.1 mm, 25 mm, UV-sterilised
n both sides, Whatman, GE Healthcare Life Sciences, PA, USA) as
reviously described [29]. Membranes were placed with the shiny
ide up onto TSAsb plates and inoculated with 50 mL of culture, and
ncubated upright (37 C, 5 % CO2), being transferred to a fresh plate
very 24 h. For colony biofilm treatment with MSlys, membranes
ere transferred to 6-well plates, and 50 mL of MSlys (final
oncentration of 4 mM) or PBS (negative control) were applied on
he whole surface and incubated for 30 min, 1 h or 2 h.
.9.1. Viable biofilm cell quantification
After MSlys or PBS treatment, the membranes were transferred
o PBS (1 mL), vortexed thoroughly, 10-fold diluted in saline, and
lated on TSAsb to quantify the number of CFUs.
.9.2. Scanning electron microscopy (SEM)
Biofilms formed on polycarbonate membranes treated with
Slys or PBS were fixed with 2.5 % (v/v) glutaraldehyde (4 C, 1 h),
nd rinsed with PBS. Samples were dehydrated in ethanol series
30, 50, 70, 80, 90 % (v/v), and absolute), sputtered with gold, and
nalyzed by SEM (FEI Quanta 650 FEG, ThermoFisher Scientific).
.9.3. Confocal laser scanning microscopy (CLSM)
Biofilms formed on polycarbonate membranes were fixed as
bove, rinsed with PBS, stained with 40,6-diamidino-2-phenyl-
ndole dihydrochloride (DAPI) according to the manufacturer’s
nstructions (Invitrogen), and analyzed by CLSM (LSM780, Zeiss,
ena, Germany).
.10. Statistical analysis
Mean and standard deviations (SD) were determined for at least
hree independent experiments. Statistical comparison was
erformed using Two-Way ANOVA and Tukey’s multiple compari-
on statistical test, using GraphPad Prism 6. Differences were




.1.1. In silico and circular dichroism (CD) analysis
The genome of the lytic Streptococcus phage MS1 was checked
or annotated endolysins. The gene ms1_61 annotated as a lysin
as identified and named mslys. MSlys consists of 295 amino acids
AA) being a modular endolysin. Bioinformatics analysis shows
hat it comprises a catalytic domain with N-acetylmuramoyl-L-
lanine amidase activity (Amidase_5; PF05382.13) and a cell-
inding domain (or choline-binding domain) composed of 5 cell-
all binding repeats (CW; PS51170) (Fig. S1). MSlys has a
heoretical MW of 34.3 kDa and a PI of 4.81. Although Pal is
MSlys and Pal were overexpressed in E. coli and purified,
showing single bands on SDS-PAGE (Fig. S3) at the expected
molecular weight (35.1 and 35.3 kDa, respectively, for MSlys and
Pal, considering the N-terminal His-tag).
The CD spectrum of Pal showed two maximum peaks (at 220
and 240 nm), one minimum peak (at 209 nm) and one shoulder (at
200 nm), while in the MSlys spectrum, two maximum peaks (at
220 and 240 nm) and only one minimum peak (at 209 nm) were
observed (Fig. 1). Estimates of secondary structures by the
deconvolution of the CD spectra indicate that both MSlys and
Pal endolysins fold predominantly in β-sheets (43 % as β-sheet, 4%
as α-helices, 21 % as turns, and 32 % unordered). This matches with
the β-sheet prevalence predicted by PSIPRED (Fig. S4).
3.1.2. Lytic spectra
The lytic spectra of MSlys (Table 1) showed high specificity
towards S. pneumoniae, killing all strains recovered from otitis
media infections. These clinical isolates were collected from male
and female children aged 1–5 years. Moreover, MSlys was effective
against encapsulated pneumococcal strains with different sero-
types, and also lysed the unencapsulated R6st (R6 streptomycin
resistant) strain and the P046 strain (double lytA lytC mutant
descended from the strain R6) (Table 1 and Fig. S5). Besides S.
pneumoniae, MSlys also lysed Streptococcus mitis while all other
streptococci and non-streptococci species were not affected by
MSlys.
3.1.3. Effect of pH, temperature, and choline on the activity of MSlys
MSlys remained active after 30 min of incubation at 37 C,
slightly decreased activity after incubation at 40 C, and became
complete inactive after incubation at 50 C (Fig. 2a). Also, MSlys
remained active between a pH of 6.0–9.0 (Fig. 2b). Supplementa-
tion of the lysis reaction with 2.5 mM or less of choline did not
significantly affect MSlys activity against S. pneumoniae after 2 h of
treatment. However, 5 mM and, more clearly, 10 mM of choline
reduced the action of MSlys against pneumococcal cells, with
20 mM of choline completely inhibiting the activity of the
endolysin.
3.2. Antibacterial activity against planktonic cells
The activity of MSlys and Pal against S. pneumoniae R6st cells
was assessed at two different concentrations (2 mM’70 mg/mL
and 4 mM’140 mg/mL) (Fig. 3).Fig. 1. Circular Dichroism spectra of pneumococcal endolysins. The spectrum of
MSlys and Pal were analyzed in the far-UV (190-260 nm) using proteins dialyzed in
PBS (pH 7.4).lready well characterized, it was subjected to the same tools for
nalysis. Thus, Pal has 296 AAs encoding an N-terminal Amidase_5
omain and a choline-binding domain containing 6 CBRs (Fig. S1),
aving a MW of 34.5 kDa and a PI of 4.95. BLASTp of MSlys showed
1 % identity with Pal, and ClustalW showed a pairwise identity of
1.4 %, showing 241 identical and 55 different amino acids (Fig. S2).4
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log10 CFU/mL) in 30 min (P  0.05) compared to the control. The
decrease continued until 2 h (2.9 log10 CFU/mL). No significant
differences were obtained between 2 and 4 mM of MSlys after 1 h
post-treatment (P > 0.05). However, after 2 h, MSlys at a final
concentration of 4 mM was significantly (P  0.05) more pro-
nounced, reducing the viable cells counts by 3.5 log10 CFU/mL.
Pal treatment at 2 mM during 30 min or 1 h resulted in no
significant differences compared with the control (P > 0.05), and
led, after 2 h, to a reduction of 0.88 log10 CFU/mL compared with
the controls. Pal at 4 mM had enhanced antibacterial effect at all
time points assessed (P  0.05), resulting in an average reduction of
1.93 log10 CFU/mL after the 2 h treatment. Nonetheless, MSlys
showed significantly higher antibacterial activity compared to Pal
(P  0.05).
3.3. Antibacterial activity of MSlys against biofilm cells
Control biofilms reached 6.39  0.57 log10 CFU/mL after 24 h
and 6.28  0.17 log10 CFU/mL after 48 h (Fig. 4). MSlys significantly
reduced the number of 24-h-old biofilms in all the time points
tested (P  0.05), reducing 0.84, 0.92, and 1.50 log10 CFU/mL after
30 min, 1 h, and 2 h, respectively. MSlys also reduced 48-h-old
biofilms, achieving approximately the same reductions (0.76, 0.80,
and 1.80 log10 CFU/mL after 30 min, 1 h, and 2 h, respectively).
S. pneumoniae usually undergo autolysis to escape phagocytosis,
but if autolysis had occurred, a CFU/mL decrease in the controls
would be observed.
The effect of 2 h of MSlys treatment on 24-h and 48-h-old
biofilms evaluated using SEM (Fig. 5) showed cells covering the
polycarbonate membrane forming in some areas thick clusters
(Fig. 5a and b). MSlys damaged the cells and increased the amount
of cell debris in the surface (Fig. 5c and d). The 48-h biofilms were
denser with thicker cell clusters (Fig. 5e and f). Once more, MSlys
was able to damage these 48-h-old biofilms, increasing the amount
of cell debris (Fig. 5g and h).
Taking into account the z-axis plot profile (mean>20), the
average thickness of the 24-h-old biofilms was 45.33  1.15 mm,
and of the 48-h-old was 132.00  28.62 mm. CLSM analysis showed
that MSlys caused changes in the biofilm thickness (Fig. 6),
indicating that this endolysin lysed pneumococcal cells within the
biofilm structures. The average thickness of 24-h-old biofilms after
MSlys treatment was 12.67  1.15 mm. The biofilm thickness
reduction was not as visible in the 24-h-old biofilms treated with
MSlys (see Fig. 6a and b), compared to the 48-h-old treated
biofilms that showed an average thickness of 87.00  4.24 mm (see
Fig. 6c and d).
4. Discussion
The virulent MS1 phage is related to phage Dp-1, presenting an
average nucleotide identity of 73.3 % on 62.3 % of the aligned
nucleotides [8]. In our study, we recombinantly expressed the
endolysin of phage MS1 (MSlys) and Pal endolysin from Dp-1.
MSlys and Pal endolysins are similar, being both modular proteins
with a catalytic module belonging to the Amidase_5 family and a
choline-binding module. The catalytic domain (N-acetylmura-
moyl-L-alanine amidase) is responsible for the cell wall degrada-
tion through hydrolysis of the amide bond between the muramic
acid and the L-alanine. The binding domain is responsible for theFig. 2. Influence of the temperature, pH and choline on the activity of MSlys. a)
The endolysin was incubated at different temperatures for 30 min, cooled on ice for
about 20 min and then used to treat S. pneumoniae cells suspended in PBS. b) The
endolysin was used to treat S. pneumoniae cells suspended in universal buffer at
5
different pH. c) The endolysin was used to treat S. pneumoniae cells suspended in
PBS containing different concentrations of choline. The reduction in the optical
density reduction of S. pneumoniae R6st cells after treatment with MSlys (2 mM) for






























M.D. Silva, H. Oliveira, A. Faustino et al. Biotechnology Reports 28 (2020) e00547ttachment to choline residues present in the pneumococcal
nvelope [30]. In silico analysis showed that the protein sequences
iffer in the number of cell wall-binding repeats (CW), with MSlys
aving 5 CW while Pal presents 6. However, the number of CW
btained differs using different software. For instance, Pal shows 6
15,30], and 7 CW in published literature [31]. Some authors
ypothesized that the affinity for choline was related to the
umber of CW. Still, other studies have refuted this assumption,
howing that the increase in the number of CW seems to be
ssociated with a stronger choline-binding, but this still needs to
e validated [15].
The antibacterial effect of MSlys was specific for S. pneumoniae,
ncluding strains isolated from the middle ear fluid of children with
titis media. It has been demonstrated that most clinical
neumococcal strains express capsule [32]. However, non-
ncapsulated S. pneumoniae (NESp) have been isolated from
atients with otitis media [33,34] and are reported as a potential
ausative agent of chronic or recurrent otitis media [35]. Although
nly a few of the middle ear fluid isolates belonging to serotypes
A/B, 11A and 19 F were identified, MSlys was effective against
strain lacking the autolysin gene, showing that its activity is
independent of the host autolysin. Besides S. pneumonie, MSlys
lysed S. mitis but did not affect other Streptococcus species tested
and non-streptococcal species. This specificity is in agreement
with previous reports for choline-binding proteins, such as Pal,
Cpl-1, and PL3 [31]. Due to the presence of the choline-binding
domain, it was already expected that MSlys would be specific for
bacteria containing choline in their cell walls. For instance, Pal and
Cpl-1 kill at a lower rate Streptococcus oralis and S. mitis, which
incorporate choline in their cell walls [9,10], and the chimeric
enzyme PL3, derived from Pal, killed S. oralis, Streptococcus
pseudopneumoniae, and S. mitis type [37]. The specific binding of
MSlys to pneumococcal strains and a few related species is
advantageous, since this provides a targeted killing and prevents
collateral effects on commensal bacteria and dysbiosis [21]. In
contrast, Cpl-7 and Cpl-7S have a different binding domain,
composed of 3 identical CW_7 tandem repeats, that confer the
ability to degrade pneumococcal cell walls containing either
choline or ethanolamine. These endolysins lyse a broader range of
bacteria, including S. pneumoniae and other Gram-positive
ig. 3. The logarithmic number of S. pneumoniae R6st cells after 30, 60, or 120 min of treatment with a) MSlys (2 or 4 mM) or b) Pal (2 or 4 mM) in comparison with
ontrol (PBS). Data are shown as mean  SD. Differences were considered statistically significant if P  0.05 (*).
ig. 4. The logarithmic number of S. pneumoniae R6st cells from a) 24-h or b) 48-h biofilms after 30, 60, or 120 min of treatment with MSlys (4 mM) in comparison with
ontrol (PBS). Data are shown as mean  SD. Differences were considered statistically significant if P  0.05 (*).hese capsule expressing strains, as well as against five other
ncapsulated S. pneumoniae strains (serotypes 1, 4, 15B/C, 19 F)
solated from sputum and blood. Some serotypes identified are
overed by the 13-valent pneumococcal conjugate vaccine (1, 4, 6A,
B, 19 F), which is included in the national immunization program
n Portugal since 2015 [36]. MSlys also killed an unencapsulated6
pathogens [38,39].
In this work, Pal structure analysis using CD agreed with a
previous report [37]. The authors theorized that the CD signature
of Streptococcus phage endolysins Pal and PL3, with two maximum
peaks (at 220240 nm) and the negative band (peak in PL3 and
shoulder in Pal at 200 nm) corresponded to a fingerprint of the
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domain, does not present a negative peak or shoulder (at 200 nm).
Both MSlys and Pal secondary structures are mostly composed of β-
sheets. In a previous study, deconvolution of the CD spectrum
showed that the secondary structure content of Pal corresponded
to 45 % β-strands, 7% α-helices, 21 % turns, and 24 % unordered [40],
being close to the values that were obtained herein. The same
authors suggested an influence of choline in the tertiary and
quaternary structures. Considering the similarity between Pal and
MSlys, the same fact can be hypothesized for MSlys. The rich β-
sheet content of Pal and MSlys are different from other
pneumococcal endolysins characterized by similar methods, such
as Cpl-7 and derived engineered enzymes (Cpl-7S, Cpl-711), which
are predicted to have rich α-helix content [38,39,41], but less
different from Cpl-1 (19 % α-helices, 32 % β-sheet, 28 % β-turn, 21 %
random coil) [42].
MSlys was stable after exposure until 37 C, with a slight
stability decrease starting at 40 C. MSlys was stable between a pH
of 6.0–9.0, just like Pal [31]. These biochemical properties are
fundamental, allowing MSlys to kill in conditions found in theFig. 5. SEM micrographs showing the effect of 2 h treatment with MSlys (4 mM) on 24 h- and 48 h-biofilms of S. pneumoniae R6st: a) and b) 24 h-biofilm control (PBS-



























M.D. Silva, H. Oliveira, A. Faustino et al. Biotechnology Reports 28 (2020) e00547iddle ear during infection. The mean ear temperature is
6.4  0.61 C, increasing by 1.0–1.5 C when feverish [43], while
he mean pH of the middle ear fluid of children with otitis media
aries between 8.55, 8.33, and 7.92 in the case of mucous, serous-
ucous, and serous secretions [44]. Being a choline-binding
rotein, MSlys might be inhibited by the presence of choline (in the
ens of millimolar range) or choline analogs, such as esters of
icyclic amines, that compete with the choline present in the
neumococcal cell wall [45]. Indeed, the activity of MSlys was
ntirely inhibited by supplementation of the lysis reaction with
0 mM of choline.
Despite the similarity between MSlys and Pal, in this study, the
ctivity of MSlys against S. pneumoniae R6st planktonic cells was
ignificantly better, after 2 h, compared to Pal using 2 and 4 mM
ndolysin concentrations. MSlys killed faster, decreasing the
umber of cells considerably after 30 min, and continued to
ecline until the end of the experiment. Overall, MSlys reduced the
umber of viable cells by 3.5 logarithmic units, whereas a
aximum decrease of 1.93 log10 CFU/mL was obtained using 4
adenoid samples from children with recurrent acute otitis media
[47]. MSlys was able to kill cells from 24 and 48-h-old biofilms,
reducing the viable cell counts after 2 h by approximately 1.5
(96.84 %) and 1.8 log10 CFU/mL (98.42 %), respectively. Pal was
previously reported to reduce nearly 90 % of biofilm-cells after 4 h
of treatment [31]. However, the authors decided to use strain P046
(a double lytA lytC mutant of the R6 strain), which is unable to
autolyze, for their biofilm assays (96-well plates,14–16 h, 34 C, 5 %
CO2). Although the method of biofilm formation used was
different, increased activity of MSlys against 24-h biofilms and
already after 2 h was observed in this study compared to reported
for Pal. In a subsequent investigation, treatment of S. pneumoniae
P046 24-h-old biofilms with the engineered endolysin Cpl-711 at
1 mg/mL for 2 h killed about 4 logs of the bacterial population. At
the same time, Cpl-1 and Cpl-7 reduced biofilms cells by
approximately 1.5 logarithmic units [41]. The activity of the
engineered endolysin is undoubtedly much higher than MSlys.
However, the values obtained with the natural phage-encoded
enzymes Cpl-1 and Cpl-7 are comparable to the ones observed for
ig. 6. CLSM micrographs (magnification 100) showing the effect of 2 h treatment with MSlys (4 mM) on 24 h- and 48 h-biofilms of S. pneumoniae R6st: a) 24 h-
iofilm control (PBS-treated); b) 24-h biofilm treated with MSlys; c) 48 h-biofilm control (PBS-treated); d) 48 h-biofilm treated with MSlys.M of Pal after 2 h. The anti-pneumococcal effect was demon-
trated to be concentration-dependent, with a lower concentration
f MSlys needed compared to Pal.
S. pneumoniae biofilms are a significant concern, having been
dentified in the middle ear mucosa specimens of children
iagnosed with chronic otitis media with effusion [46] and in8
MSlys. The synergy between the enzymes Cpl-711 and PL3 against
S. pneumoniae biofilms formed at 34 C for 1416 h was also
reported [48]. Treatment with the combination of 0.5  MIC of the
endolysins for 1 h reduced cells in biofilms by more than 4.0 log10
CFU/mL, representing an increase of 3.6 logs compared to the sum
of activities of the individual Cpl-711 or PL3 treatments. So,
M.D. Silva, H. Oliveira, A. Faustino et al. Biotechnology Reports 28 (2020) e00547combining MSlys with another endolysin can be another strategy
to enhance their antibacterial activity against pneumococcal
biofilms. The potential of MSlys against pneumococcal biofilms
was corroborated by SEM, where damaged cells and an increase of
cell debris due to the endolysin were observed, and also by CLSM,
where a significant difference in biofilm thickness was observed
between treated and control samples. This result seems to be
similar to the one obtained by previous authors [31]. These authors
showed that two S. pneumoniae endolysins disintegrated biofilm,
analysed by crystal violet (CV) staining of the total biofilm biomass,
resulting in a reduction of around 70 % (Cpl-7), and 55 % (Cpl-1).
Due to the similarity between MSlys and Pal, one would expect that
their action towards biofilms would be comparable. However, this
was not observed since Pal did not damage the biofilm structures
as analyzed both by CLSM and CV staining [31].
During the last few years, protein engineering has improved
properties of S. pneumoniae endolysins, i.e., has amplified their
antimicrobial activity, increased their plasma half-time, and their
capacity to pass through the negatively charged bacterial envelope.
These improvements have been accomplished by the inclusion of
new residues (Cpl-1 dimer) [49], inversion of the charge of the cell
wall binding domain (Cpl-7S) [39], and domain swapping/fusion
(Cpl-711, PL3) [37,41]. The natural MSlys is not as efficient as
engineered endolysins; nevertheless, it presents excellent features
against S. pneumoniae.
In summary, we characterized a novel natural pneumococcal
endolysin, which is structurally very similar to Pal. MSlys was
shown to be very effective against S. pneumoniae planktonic and
biofilm cells. Furthermore, we showed that its activity is specific
for S. pneumoniae and S. mitis, lysing pneumococcal strains isolated
from otitis media infections. Also, MSlys was shown to be active in
conditions commonly found in the middle ear during disease.
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